Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
Yoon
Sang Hyun
SH
Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kim
Ki Hyang
KH
Choi
Junjeong
J
Kim
Gun Min
GM
Kim
Joo Hoon
JH
Kim
Hyo Song
HS
Park
Young Nyun
YN
Rha
Sun Young
SY